Atheneum Pharmaceuticals Receives $60 Million Upfront Payment from UCB for ATG-201

Atheneum Pharmaceuticals has received a $60 million upfront payment from UCB for ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody. The payment follows a global exclusive licensing agreement signed in March. The upfront funding strengthens the company's cash position to advance its innovative pipeline.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments